Inclusion Criteria:

- adult patients, >=18 years of age;

- centrally confirmed EGFR expression in tumor tissue;

- radiologically measurable or clinically evaluable disease;

- last dose of systemic anti-neoplastic therapy or radiotherapy >=28 days prior to
start of study;

- histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+
solid tumors (Part 1);

- histologically or cytologically confirmed advanced stage, primary or metastatic EGFR+
and mutant KRAS colorectal cancer (Part 2);

- not more than 2 previous cytotoxic regimens for metastatic disease (Part 2).

Exclusion Criteria:

- history of grade 3-4 toxicity resulting from previous anti-EGFR treatment;

- known or suspected CNS metastases;

- wild type KRAS colorectal cancer (Part 2).